FDA Prepares Drugmakers for Future-Compatible Electronic Submission Standards
Published Date: 10/16/2026
Notice
Summary
The FDA is getting ready to support a new way of submitting drug and biologic info electronically called eCTD 4.0 starting October 16, 2026. This update helps companies send their data in a future-proof format, making reviews smoother and faster. If you work in drug or biologic development, this change affects how you submit your paperwork, but there’s no new cost announced yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA to accept eCTD v4.0 forward-compatible submissions
If you submit drug or biologic applications, FDA will begin accepting eCTD Version 4.0 Forward Compatibility electronic submissions on October 16, 2026. The Forward Compatibility capability lets FDA process eCTD v4.0 submissions for applications originally submitted using eCTD v3.2.2, so industry can transition to v4.0 while retaining access to prior lifecycle content.
Requirement to use FDA-supported eCTD version for covered submissions
Submissions that are subject to section 745A(a) of the Federal Food, Drug, and Cosmetic Act must be submitted in eCTD format using the version of eCTD currently supported by FDA, unless the submission is exempt or FDA grants a waiver. The currently supported eCTD version is listed in the FDA Data Standards Catalog.
No new costs announced for eCTD v4.0 support
The notice announces FDA readiness to receive eCTD v4.0 Forward Compatibility submissions beginning October 16, 2026, and does not announce any new fees or costs associated with that support.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-21196, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Alaska Region Amendment 80 Program
NOAA is asking to keep collecting info from 7 fishing businesses in Alaska to manage the Amendment 80 Program, which controls fishing rules in the Bering Sea and Aleutian Islands. This update extends the current paperwork, which takes about 14 hours total each year, with no new fees or big changes. They’re giving the public 30 more days to share thoughts before final approval.
Next: 2026-21198, Agency Information Collection Activities; Proposed Collection; Comments Requested; Revising a Previously Approved Collection; ATF Adjunct Instructor Data-ATF Form 6140.3
The ATF is updating a form used to collect info from their adjunct instructors and wants your feedback by December 15, 2026. This update helps keep their records accurate and useful without adding extra hassle. If you’re involved with ATF training or just curious, now’s the time to speak up!